ODTX (Odyssey Therapeutics) Total Liabilities: $752.76 Mil (As of Mar. 2026)


ODTX Odyssey Therapeutics Inc ODTX
9 GF Score
Price $19.23
! 2 Warning Signs
View Full Analysis

What is Odyssey Therapeutics Total Liabilities?

Odyssey Therapeutics ODTX +1.91% 9 Total Liabilities is $752.76 Mil as of Mar. 2026. GuruFocus rates ODTX with a GF Score™ of 9/100. The stock has 2 warning signs investors should review.

Odyssey Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 was $752.76 Mil.

Odyssey Therapeutics's quarterly Total Liabilities increased from Mar. 2025 ($0.00 Mil) to Dec. 2025 ($758.07 Mil) but then declined from Dec. 2025 ($758.07 Mil) to Mar. 2026 ($752.76 Mil).

Odyssey Therapeutics's annual Total Liabilities increased from Dec. 2023 ($549.23 Mil) to Dec. 2024 ($579.96 Mil) and increased from Dec. 2024 ($579.96 Mil) to Dec. 2025 ($758.07 Mil).

Odyssey Therapeutics Total Liabilities Historical Data

* Premium members only.

The historical data trend for Odyssey Therapeutics's Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Odyssey Therapeutics Total Liabilities Chart

Odyssey Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
Total Liabilities
461.77 549.23 579.96 758.07

Odyssey Therapeutics Quarterly Data
Dec22 Dec23 Sep24 Dec24 Mar25 Dec25 Mar26
Total Liabilities Get a 7-Day Free Trial 570.80 579.96 0.00 758.07 752.76
ODTX
9GF Score
Odyssey Therapeutics Inc ODTX
Total Liabilities is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Odyssey Therapeutics Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

Odyssey Therapeutics's Total Liabilities for the fiscal year that ended in Dec. 2025 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=26.475+(21.9+709.691
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=758.07

Total Liabilities=Total Assets (A: Dec. 2025 )-Total Equity (A: Dec. 2025 )
=269.788--488.278
=758.07

Odyssey Therapeutics's Total Liabilities for the quarter that ended in Mar. 2026 is calculated as

Total Liabilities=Total Current Liabilities+Total Noncurrent Liabilities
=Total Current Liabilities+(Long-Term Debt & Capital Lease Obligation+Other Long-Term Liabilities
=22.211+(20.753+709.8
+NonCurrent Deferred Liabilities+PensionAndRetirementBenefit+NonCurrent Deferred Income Tax)
+0+0+0)
=752.76

Total Liabilities=Total Assets (Q: Mar. 2026 )-Total Equity (Q: Mar. 2026 )
=229.07--523.694
=752.76

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Total Liabilities →
What does a Total Liabilities of $752.76 Mil mean?
Odyssey Therapeutics (ODTX) has a Total Liabilities of $752.76 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Odyssey Therapeutics and its competitors.
Is Odyssey Therapeutics' Total Liabilities too high?
Odyssey Therapeutics' current Total Liabilities is $752.76 Mil. Overall, Odyssey Therapeutics has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Odyssey Therapeutics' Total Liabilities compare to VOR and PHAT?
Odyssey Therapeutics' Total Liabilities of $752.76 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Biotechnology company?
A good Total Liabilities depends on the Biotechnology industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for Odyssey Therapeutics and its competitors. Odyssey Therapeutics's current Total Liabilities is $752.76 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Odyssey Therapeutics stock overvalued right now?
Odyssey Therapeutics (ODTX) has a current Total Liabilities of $752.76 Mil. The current Total Liabilities is $752.76 Mil. Odyssey Therapeutics' overall GF Score™ is 9/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For Odyssey Therapeutics (ODTX), the current Total Liabilities is $752.76 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Odyssey Therapeutics Business Description

Address 51 Sleeper Street, Boston, MA, USA, 02210
Odyssey Therapeutics Inc is a clinical-stage biopharmaceutical company seeking to transform the standard of care for patients suffering from autoimmune and inflammatory diseases. The Company is developing medicines that are designed to precisely target disease pathology with an initial emphasis on the innate immune system. Its programs include OD-07656, a small molecule scaffolding inhibitor of receptor-interacting protein kinase 2, or RIPK2, a small molecule scaffolding inhibitor of interleukin-1 receptor-associated kinase 4, or IRAK4, and OD-00910, an agonistic protein therapeutic targeting tumor necrosis factor receptor 2, or TNFR2, built from camelid heavy chain variable regions, or VHH, domains.
9GF Score

Get the complete analysis for ODTX

Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$19.23
Price